Dementia disorders present one of today's most devastating and costly challenges. It is estimated that there are currently over 5 million patients with Alzheimer's Disease in the United States alone, with 12 million additional patients with Mild Cognitive Impairment, and 78 million baby boomers approaching the age at which these disorders may begin. Published data indicates that up to 50% of the people who have Alzheimer's Disease have not been diagnosed, and misdiagnosis rates reach 20% even in leading clinical centers. Clinicians, caregivers, and families seek a definitive diagnosis in order to provide proper care. Early detection is vital, as even today's drugs can defer symptom progression when in early stages. Predictive diagnosis and response detection will become even more critical as promising pipeline drugs become available for specific dementias. Similarly, objective measures of disease and treatment response are important in order to evaluate and progress promising drug candidates. Imaging of the brain using Positron Emission Tomography (PET) can provide objective, predictive information regarding the type and progression stage of dementia. However, available analysis tools capture only a subset of the image information required to achieve the accuracy, specificity, prediction, and interpretability necessary to impact patient care and allow broader adoption. The need remains for a practical solution that can provide tangible diagnostic and therapeutic value, and an informative endpoint for drug developers. This solution must be able to measure and make sense of complex and often subtle brain signal information that can predict and accurately distinguish among dementias. It must also be developed with a focus on the ordering physician's ability to make use of the information. Building upon three important advances in the processing and analysis of PET image data, we are developing an accurate, predictive, and commercially practical imaging diagnostic tool to assist in the diagnosis and development of effective therapeutics for patients with major neurodegenerative dementing disorders. These include Alzheimers Disease (AD), Lewy Body Dementia (DLB), and frontotemporal dementia (FTD), beginning with their earliest presymptomatic stages. The product would provide three significant benefits over other approaches: (1) superior accuracy and specificity, (2) early prediction of decline or response, and (3) practicality and clinical relevance allowing broad adoption. Our work builds upon advances in the analysis of Positron Emission Tomography (PET) imaging and Magnetic Resonance Imaging (MRI) developed at New York University (NYU), and their integration with advanced pattern recognition algorithms and user focused design. The advances are significant because they allow measurement of regions that are early predictors of decline, and which distinguish the different forms of dementia. The pattern recognition we will employ is able to identify and quantify the complex changes associated with these dementias and make them interpretable for clinical use. The NYU approach has already been applied successfully to over 650 patients from multiple imaging sites, and using data collected through the Alzheimer's Disease Neuroimaging Initiatve (ADNI) program. The pattern recognition has been applied successfully in our drug development studies and to a pilot set of Alzheimer's data. This research and the positive results achieved have created a path to successful development. The commercial application of this work is twofold: (1) a diagnostic service and potentially licensable software package, where the customer audience includes radiologists, neurologists, general practitioners, and ultimately the general population as screening may be adopted over time; and (2) use in drug development trials. Abiant, Inc. is a privately held company that provides imaging studies and data analysis services to pharmaceutical companies to assist in development decision making. Abiant's business model includes current revenues from imaging studies and data analysis performed for pharmaceutical companies, future diagnostic offerings, and participation in novel compound upside through collaborative relationships. This proposed work is a logical extension of Abiant's current core business of providing PET imaging studies to pharmaceutical companies to evaluate new therapeutic compounds targeted to the central nervous system, and the company's integration of advanced technology with commercial utility.